Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques
Matthew S. Parsons, … , Miles P. Davenport, Stephen J. Kent
Matthew S. Parsons, … , Miles P. Davenport, Stephen J. Kent
Published November 26, 2018
Citation Information: J Clin Invest. 2019;129(1):182-191. https://doi.org/10.1172/JCI122466.
View: Text | PDF
Research Article AIDS/HIV Immunology Article has an altmetric score of 4

Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques

  • Text
  • PDF
Abstract

A considerable body of evidence suggests that Fc-dependent functions improve the capacity of broadly neutralizing antibodies (BnAbs) to protect against and control HIV-1 infection. This phenomenon, however, has not been formally tested in robust cell-associated macaque simian-human immunodeficiency virus (SHIV) models with newer-generation BnAbs. We studied both the WT BnAb PGT121 and a LALA mutant of PGT121 (which has impaired Fc-dependent functions) for their ability to protect pigtail macaques from an i.v. high-dose cell-associated SHIVSF162P3 challenge. We found that both WT and LALA PGT121 completely protected all 12 macaques studied. Further, partial depletion of NK cells, key mediators of Fc-dependent functions, did not abrogate the protective efficacy of PGT121 in 6 macaques. Additionally, in animals with established SHIVSF162P3 infection, SHIV viremia levels were equally rapidly reduced by LALA and WT PGT121. Our studies suggest that the potent neutralizing capacity of PGT121 renders the Fc-dependent functions of the Ab at least partially redundant. These findings have implications for Ab-mediated protection from and control of HIV-1 infection.

Authors

Matthew S. Parsons, Wen Shi Lee, Anne B. Kristensen, Thakshila Amarasena, Georges Khoury, Adam K. Wheatley, Arnold Reynaldi, Bruce D. Wines, P. Mark Hogarth, Miles P. Davenport, Stephen J. Kent

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2009 Total
Citations: 3 4 7 8 18 8 10 1 1 60
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (60)

Title and authors Publication Year
SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants
King HA, Brammer D, Lewitus E, Fennessey CM, Manalang KM, Shrader HR, Andrew S, Kuri P, Lind M, Pham P, Sanders-Buell E, Bai H, Mason R, Song K, McCarthy E, Helmold Hait S, Todd JP, Pegu A, Foulds KE, Lifson JD, Keele BF, Rolland M, Roederer M, Bolton DL
Proceedings of the National Academy of Sciences of the United States of America 2025
Afucosylated broadly neutralizing antibodies targeting the HIV envelope elicit enhanced NK-cell–mediated cytotoxicity against HIV-infected CD4+ T-cell and macrophage targets
Wilhelm O, Jordan C, Kek H, Brunton-O\u2019Sullivan MM, Rikard-Bell L, Ramanathan P, Chung AW, Poumbourios P, Wines BD, Jaworowski A, Hearps AC
Journal of Leukocyte Biology 2025
A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer.
Wang Y, Ji P, Liu Q, Jia N, Ma Y, Yuan T, Rehati P, Chen J, Wen Y, Wu F, Huang J
Cell discovery 2025
Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention
Becerra JC, Hitchcock L, Vu K, Gach JS
Microbial Cell 2024
Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing
de Taeye SW, Schriek AI, Umotoy JC, Grobben M, Burger JA, Sanders RW, Vidarsson G, Wuhrer M, Falck D, Kootstra NA, van Gils MJ
Communications biology 2024
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIVAD8-EO infection
Dias J, Fabozzi G, Fourati S, Chen X, Liu C, Ambrozak DR, Ransier A, Laboune F, Hu J, Shi W, March K, Maximova AA, Schmidt SD, Samsel J, Talana CA, Ernste K, Ko SH, Lucas ME, Radecki PE, Boswell KL, Nishimura Y, Todd JP, Martin MA, Petrovas C, Boritz EA, Doria-Rose NA, Douek DC, Sékaly RP, Lifson JD, Asokan M, Gama L, Mascola JR, Pegu A, Koup RA
Nature Communications 2024
Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection
Richel E, Cordsmeier A, Bauer L, Fraedrich K, Vestweber R, Roshani B, Stolte-Leeb N, Ensser A, Stahl-Hennig C, Überla K
PLOS Pathogens 2024
Phenotypic and functional characterization of pharmacologically expanded Vγ9Vδ2 T cells in pigtail macaques
Barber-Axthelm IM, Wragg KM, Esterbauer R, Amarasena TH, Barber-Axthelm VR, Wheatley AK, Gibbon AM, Kent SJ, Juno JA
iScience 2023
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Burton DR
Nature reviews. Immunology 2023
Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure
Karunasinee Suphaphiphat, Delphine Desjardins, Valérie Lorin, Nastasia Dimant, Kawthar Bouchemal, Laetitia Bossevot, Maxence Galpin-Lebreau, Nathalie Dereuddre-Bosquet, Hugo Mouquet, Roger Le Grand, Mariangela Cavarelli
Nature Communications 2023
Complement contributes to antibody-mediated protection against repeated SHIV challenge
Goldberg BS, Spencer DA, Pandey S, Ordonez T, Barnette P, Yu Y, Gao L, Dufloo J, Bruel T, Schwartz O, Ackerman ME, Hessell AJ
Proceedings of the National Academy of Sciences 2023
Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein.
Grunst MW, Ladd RA, Clark NM, Gil HM, Klenchin VA, Mason R, Franchini G, Roederer M, Evans DT
PLoS pathogens 2023
Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
Haycroft ER, Damelang T, Lopez E, Rodgers MA, Wines BD, Hogarth M, Ameel CL, Kent SJ, Scanga CA, O'Connor SL, Chung AW
IBMS BoneKEy 2023
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
Tieu HV, Karuna S, Huang Y, Sobieszczyk ME, Zheng H, Tomaras GD, Montefiori DC, Shen M, DeRosa S, Cohen K, Isaacs MB, Regenold S, Heptinstall J, Seaton KE, Sawant S, Furch B, Pensiero M, Corey L, Bar KJ
Vaccine 2023
Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis
D Spencer, B Goldberg, S Pandey, T Ordonez, J Dufloo, P Barnette, W Sutton, H Henderson, R Agnor, L Gao, T Bruel, O Schwartz, N Haigwood, M Ackerman, A Hessell
Nature Communications 2022
Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice
C Hioe, G Li, X Liu, O Tsahouridis, X He, M Funaki, J Klingler, A Tang, R Feyznezhad, D Heindel, X Wang, D Spencer, G Hu, N Satija, J Prévost, A Finzi, A Hessell, S Wang, S Lu, B Chen, S Zolla-Pazner, C Upadhyay, R Alvarez, L Su, D Douek
PLoS pathogens 2022
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses
P Klasse, J Moore, G Silvestri
Journal of virology 2022
Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
J Dufloo, C Planchais, S Frémont, V Lorin, F Guivel-Benhassine, K Stefic, N Casartelli, A Echard, P Roingeard, H Mouquet, O Schwartz, T Bruel
Nature Communications 2022
A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 delta infection
N Routhu, S Gangadhara, L Lai, M Gardner, K Floyd, A Shiferaw, Y Bartsch, S Fischinger, G Khoury, S Rahman, S Stampfer, A Schaefer, S Jean, C Wallace, R Stammen, J Wood, J Cohen, T Nagy, M Parsons, L Gralinski, P Kozlowski, G Alter, M Suthar, R Amara
Science Immunology 2022
Assessment of Fcγ receptor-dependent binding of influenza hemagglutinin vaccine-induced antibodies in a non-human primate model
Masuta Y, Takahama S, Nogimori T, Moriyama S, Takahashi Y, Yamamoto T
iScience 2022
Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice.
Brady JM, Phelps M, MacDonald SW, Lam EC, Nitido A, Parsons D, Boutros CL, Deal CE, Garcia-Beltran WF, Tanno S, Natarajan H, Ackerman ME, Vrbanac VD, Balazs AB
Science Translational Medicine 2022
HIV-1 Vpu restricts Fc-mediated effector functions in vivo
Prévost J, Anand SP, Rajashekar JK, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-Lepage G, Chen HC, Chen Y, Horwitz JA, Grunst MW, Zolla-Pazner S, Haynes BF, Burton DR, Flavell RA, Kirchhoff F, Hahn BH, Smith AB III, Pazgier M, Nussenzweig MC, Kumar P, Finzi A
Cell Reports 2022
Are Fc Gamma Receptor Polymorphisms Important in HIV-1 Infection Outcomes and Latent Reservoir Size?
H Lamptey, EY Bonney, B Adu, GB Kyei
Frontiers in immunology 2021
Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
DA Spencer, MB Shapiro, NL Haigwood, AJ Hessell
Frontiers in public health 2021
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
R Duerr, KM Crosse, AM Valero-Jimenez, M Dittmann
Microorganisms 2021
Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection
BM Gunn, S Bai
Human Vaccines & Immunotherapeutics 2021
Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features
HD Cheng, KG Dowell, C Bailey-Kellogg, BA Goods, JC Love, G Ferrari, G Alter, J Gach, DN Forthal, GK Lewis, K Greene, H Gao, DC Montefiori, ME Ackerman
Retrovirology 2021
Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies
T Noy-Porat, A Edri, R Alcalay, E Makdasi, D Gur, M Aftalion, Y Evgy, A Beth-Din, Y Levy, E Epstein, O Radinsky, A Zauberman, S Lazar, S Yitzhaki, H Marcus, A Porgador, R Rosenfeld, O Mazor
Antibodies 2021
Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies
JM Edwards, B Heydarchi, G Khoury, NA Salazar-Quiroz, CA Gonelli, B Wines, PM Hogarth, AB Kristensen, MS Parsons, DF Purcell, F Kirchhoff
Journal of virology 2021
Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity
BS Goldberg, CI Kaku, J Dufloo, T Bruel, O Schwartz, DA Spencer, AJ Hessell, ME Ackerman, M Caskey, L Pirofski
mBio 2021
TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure
CT Hvilsom, OS Søgaard
Frontiers in immunology 2021
Broadly Neutralizing Antibodies for HIV-1 Prevention
SR Walsh, MS Seaman
Frontiers in immunology 2021
Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis
JM Turman, AM Cheplowitz, C Tiwari, T Thomas, D Joshi, M Bhat, Q Wu, E Pong, SY Chu, DE Szymkowski, A Sharma, S Seveau, JM Robinson, JJ Kwiek, D Burton, MV Rajaram, J Kim, L Hangartner, LP Ganesan
Journal of immunology (Baltimore, Md. : 1950) 2021
Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates
L Hangartner, D Beauparlant, E Rakasz, R Nedellec, N Hozé, K McKenney, MA Martins, GE Seabright, JD Allen, AM Weiler, TC Friedrich, RR Regoes, M Crispin, DR Burton
Science Translational Medicine 2021
Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues
AM Carias, JR Schneider, P Madden, R Lorenzo-Redondo, M Araínga, A Pegu, GC Cianci, D Maric, F Villinger, JR Mascola, RS Veazey, TJ Hope
Journal of immunology (Baltimore, Md. : 1950) 2021
Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure
MS Parsons, AB Kristensen, KJ Selva, WS Lee, T Amarasena, R Esterbauer, AK Wheatley, BR Bavinton, AD Kelleher, AE Grulich, G Khoury, JA Juno, SJ Kent
EBioMedicine 2021
Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis
M Phelps, AB Balazs
Frontiers in immunology 2021
Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells
SP Anand, S Ding, WD Tolbert, J Prévost, J Richard, HM Gil, G Gendron-Lepage, WF Cheung, H Wang, R Pastora, H Saxena, W Wakarchuk, H Medjahed, BD Wines, M Hogarth, GM Shaw, MA Martin, DR Burton, L Hangartner, DT Evans, M Pazgier, D Cossar, MD McLean, A Finzi, V Simon
Journal of virology 2021
Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121
WS Lee, A Reynaldi, T Amarasena, MP Davenport, MS Parsons, SJ Kent
Frontiers in immunology 2021
A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
MM Lemke, MR McLean, CY Lee, E Lopez, ER Bozich, S Rerks-Ngarm, P Pitisuttithum, S Nitayaphan, S Kratochvil, BD Wines, PM Hogarth, SJ Kent, AW Chung, KB Arnold
Cell reports. Medicine 2021
Improved Killing of HIV-infected Cells Using Three Neutralizing and Non-neutralizing Antibodies
Marina Tuyishime, Carolina Garrido, Shalini Jha, Matthew Moeser, Dieter Mielke, Celia LaBranche, David Montefiori, Barton F. Haynes, Sarah B. Joseph, David M. Margolis, Guido Ferrari
Journal of Clinical Investigation 2020
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
WS Lee, AK Wheatley, SJ Kent, BJ DeKosky
Nature Microbiology 2020
Recent insights into Fc-mediated effector responses to HIV-1
MC Carpenter, ME Ackerman
Current Opinion in HIV and AIDS 2020
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo
P Wang, MR Gajjar, J Yu, NN Padte, A Gettie, JL Blanchard, K Russell-Lodrigue, LE Liao, AS Perelson, Y Huang, DD Ho
Proceedings of the National Academy of Sciences 2020
Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV
Y Ren, M Korom, AR Ward, R Truong, D Chan, SH Huang, CM Kovacs, E Benko, JT Safrit, J Lee, H Garbán, R Lynch, RB Jones, G Silvestri
Journal of virology 2020
Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques
Z Li, M Khanna, SL Grimley, P Ellenberg, CA Gonelli, WS Lee, TH Amarasena, AD Kelleher, DF Purcell, SJ Kent, C Ranasinghe
Scientific Reports 2020
Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
MB Shapiro, T Cheever, DC Malherbe, S Pandey, J Reed, ES Yang, K Wang, A Pegu, X Chen, D Siess, D Burke, H Henderson, R Lewinsohn, M Fischer, JJ Stanton, MK Axthelm, C Kahl, B Park, AD Lewis, JB Sacha, JR Mascola, AJ Hessell, NL Haigwood
Nature Communications 2020
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody
M Asokan, J Dias, C Liu, A Maximova, K Ernste, A Pegu, K McKee, W Shi, X Chen, C Almasri, W Promsote, DR Ambrozak, L Gama, J Hu, DC Douek, JP Todd, JD Lifson, S Fourati, RP Sekaly, AR Crowley, ME Ackerman, SH Ko, D Kilam, EA Boritz, LE Liao, K Best, AS Perelson, JR Mascola, RA Koup
Proceedings of the National Academy of Sciences 2020
Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1
GK Lewis, ME Ackerman, G Scarlatti, C Moog, M Robert-Guroff, SJ Kent, J Overbaugh, RK Reeves, G Ferrari, B Thyagarajan
Frontiers in immunology 2019
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
MZ Tay, K Wiehe, J Pollara
Frontiers in immunology 2019
Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections
SP Anand, A Finzi
Human vaccines 2019
A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities
JR Schneider, X Shen, C Orlandi, T Nyanhete, S Sawant, AM Carias, AD Smith, NL Kelleher, RS Veazey, GK Lewis, GD Tomaras, TJ Hope, G Silvestri
Journal of virology 2019
Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization
B Su, S Dispinseri, V Iannone, T Zhang, H Wu, R Carapito, S Bahram, G Scarlatti, C Moog
Frontiers in immunology 2019
Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function
AR Crowley, ME Ackerman
Frontiers in immunology 2019
Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1:
S Pittala, KS Morrison, ME Ackerman
Current Opinion in HIV and AIDS 2019
V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers
R Duerr, MK Gorny
Human vaccines 2019
Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity
H Sojar, S Baron, JT Sullivan, M Garrett, MM van Haaren, J Hoffman, J Overbaugh, BJ Doranz, MD Hicar, F Kirchhoff
Journal of virology 2019
Antibody responses to the HIV-1 envelope high mannose patch
Christine N Daniels, Kevin O Saunders
Advances in immunology 2019
Blocking HIV-1 replication: are Fc-Fcγ receptor interactions required?
Don Forthal, Andres Finzi
Journal of Clinical Investigation 2018
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 6 X users
Reddited by 1
51 readers on Mendeley
See more details